Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

European approval for Abbott's new ovarian cancer diagnostic test

A new diagnostic tool, which studies show can aid in determining the risk of whether a pelvic mass is benign or malignant, is now available in Europe. This simple blood test is expected to help in the assessment of epithelial ovarian cancer, the most lethal form of gynecological cancer.

14 Jan 2010

TD2 and COTI work together to obtain approval of clinical trials for COTI-2

TGen Drug Development (TD2) and Critical Outcome Technologies Inc. (COTI) (TSXV:COT) announced today that they will work together to obtain approval of clinical trials for a promising new anti-cancer drug called COTI-2.

12 Jan 2010

Preliminary results from Nektar Therapeutics' NKTR-102 Phase 2 study in platinum-resistant ovarian cancer

Nektar Therapeutics today announced preliminary results from the first stage of a two-stage Phase 2 clinical study evaluating NKTR-102 in women with platinum-resistant ovarian cancer. In the first stage of the study, 39 patients enrolled with platinum-resistant disease were evaluable for the primary endpoint of overall response rate using Gynecologic Cancer InterGroup (GCIG) criteria, i.e., a combination of response by tumor imaging

12 Jan 2010

PET-CT imaging appears to detect cancer in patients with neurologic complications

A combined positron emission tomography-computed tomography (PET-CT) scan of the whole body appears to detect cancer in individuals with related neurologic complications more accurately than some other commonly used tests, according to a report posted online today that will appear in the March print issue of Archives of Neurology, one of the JAMA/Archives journals.

12 Jan 2010

LehmanMillet adds two new accounts: Myriad Genetics and Breathe Technologies

HealthSTAR's LehmanMillet, the leading agency devoted to working with health care companies changing standards of care, today announced the addition of two new accounts: Myriad Genetics and Breathe Technologies.

9 Jan 2010

Novelos Therapeutics to conclude pivotal Phase 3 trial in advanced non-small cell lung cancer

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the 725th event (patient death) has been reached in its pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) studying its lead product, NOV-002, in combination with first-line chemotherapy.

8 Jan 2010

Access Pharmaceuticals completes enrollment for Prolindac monotherapy trail, begins combination study

ACCESS PHARMACEUTICALS, INC., today announced that it has completed enrollment and evaluation of the last additional cohort of patients in the ongoing clinical study of ProLindac as a monotherapy in ovarian cancer patients who have received at least two prior platinum based treatment regimens.

8 Jan 2010

MabCure signs clinical research agreement to diagnose ovarian cancer

MabCure, N.V. (“MabCure”) a wholly-owned subsidiary of MabCure Inc., a biotech company that has developed a series of highly specific monoclonal antibodies (MAbs) to combat various types of cancers, has signed a clinical research agreement with the Ramathibodi Hospital, Mahidol University in Bangkok, Thailand.

7 Jan 2010

OncoGenex Pharmaceuticals receives grant funding for Phase 2 clinical trial of OGX-427

OncoGenex Pharmaceuticals, Inc., today announced that a randomized, controlled, investigator-sponsored Phase 2 clinical trial evaluating OGX-427 when administered as a monotherapy to patients with castrate resistant prostate cancer (CRPC) has received grant funding.

6 Jan 2010

Multivariable analyses identify epidemiological risk factors for ovarian cancer

Concentrations of the biomarkers CA125, human epididymis protein 4 (HE4), and mesothelin began to rise 3 years before clinical diagnosis of ovarian cancer, according to a new study published online December 30 in the Journal of the National Cancer Institute. However, the biomarkers became substantially elevated only in the last year prior to diagnosis.

31 Dec 2009

Music stars join hands to show how young people can help build a world without cancer

Some of the nation's rising music stars have joined the nation's first cancer center in an effort to show young people that they can help build a world without cancer. Roswell Park Cancer Institute created a new hip hop song and video called "How Big Is Your Heart." The MTV-like commercial features cancer patients and nurses dancing alongside professional dancers through the halls and lobby of the cancer hospital.

31 Dec 2009

Vermillion signs securities purchase agreements with investors

Vermillion, Inc., today announced that it entered into securities purchase agreements in connection with a private placement with a group of investors effective December 24, 2009.

28 Dec 2009

Arrayit achieves technological breakthrough in microarray production

Arrayit Corporation, a life sciences and healthcare technology leader, today announced that the Company has made a technological breakthrough in the speed and efficiency by which it manufactures its proprietary microarrays, which are tiny glass substrates that contain rows and columns of printed spots used for scientific research and molecular diagnostics.

22 Dec 2009

Possible link between presence of breast cancer genes and infertility discovered

A New York Medical College physician who specializes in restoring or preserving fertility in female cancer patients has discovered a possible link between the presence of breast cancer genes and infertility.

19 Dec 2009

Arrayit Diagnostics to begin marketing its OvaDx Pre-Symptomatic Ovarian Cancer Blood Test in 2010

John Howell, CEO of Arrayit Diagnostics, Inc., a majority-owned subsidiary of Arrayit Corporation (OTC Bulletin Board: ARYC), today formally commented on the anticipated timeline for commercialization of its microarray-based OvaDx(TM) Pre-Symptomatic Ovarian Cancer Blood Test, which is currently advancing through late-stage development - the rights to which have been assigned exclusively to the Company by Arrayit Corporation.

17 Dec 2009

$15 million federal funds for new cancer research program

As a result of C3: Colorectal Cancer Coalition's advocacy efforts, $15 million for a new peer reviewed cancer research program is included in the final Fiscal Year 2010 Defense Appropriations Bill.

17 Dec 2009

Nanoparticle could allow diagnosis and treatment in one visit

Researchers at Rice University and Baylor College of Medicine (BCM) have created a single nanoparticle that can be tracked in real time with MRI as it homes in on cancer cells, tags them with a fluorescent dye and kills them with heat.

15 Dec 2009

Study examines the association of BRCA1 gene, infertility and breast/ovarian cancer

In a study published online this week in the leading cancer journal, Journal of Clinical Oncology, Westchester Medical Center Physician Dr. Kutluk Oktay, MD, Director, Division of Reproductive Medicine & Infertility concluded that mutations in the BRCA1 gene (gene associated with early onset breast cancer) are associated with early diminishment of egg reserve.

14 Dec 2009

Eli Lilly provides financial guidance for 2010

At its annual meeting today with the investment community, Eli Lilly and Company highlighted how its innovation-based strategy will enable it to better serve patients and compete effectively in a challenging health care environment. The company also detailed the progress being made in its labs and across its five new business units on an expanding pipeline of innovative molecules and marketed medicines, and provided investors with the company's financial guidance for 2010.

10 Dec 2009

Arrayit Diagnostics signs exclusive License Agreement with Wayne State University

Arrayit Diagnostics, Inc., a majority-owned subsidiary of Arrayit Corporation (OTC Bulletin Board: ARYC), today announced that it has signed an exclusive License Agreement with Wayne State University to key intellectual property covering discoveries of biomarkers of ovarian cancer.

10 Dec 2009

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

European approval for Abbott's new ovarian cancer diagnostic test

TD2 and COTI work together to obtain approval of clinical trials for COTI-2

Preliminary results from Nektar Therapeutics' NKTR-102 Phase 2 study in platinum-resistant ovarian cancer

PET-CT imaging appears to detect cancer in patients with neurologic complications

LehmanMillet adds two new accounts: Myriad Genetics and Breathe Technologies

Novelos Therapeutics to conclude pivotal Phase 3 trial in advanced non-small cell lung cancer

Access Pharmaceuticals completes enrollment for Prolindac monotherapy trail, begins combination study

MabCure signs clinical research agreement to diagnose ovarian cancer

OncoGenex Pharmaceuticals receives grant funding for Phase 2 clinical trial of OGX-427

Multivariable analyses identify epidemiological risk factors for ovarian cancer

Music stars join hands to show how young people can help build a world without cancer

Vermillion signs securities purchase agreements with investors

Arrayit achieves technological breakthrough in microarray production

Possible link between presence of breast cancer genes and infertility discovered

Arrayit Diagnostics to begin marketing its OvaDx Pre-Symptomatic Ovarian Cancer Blood Test in 2010

$15 million federal funds for new cancer research program

Nanoparticle could allow diagnosis and treatment in one visit

Study examines the association of BRCA1 gene, infertility and breast/ovarian cancer

Eli Lilly provides financial guidance for 2010

Arrayit Diagnostics signs exclusive License Agreement with Wayne State University

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in